New hope for kidney disease: drug shows promise in slowing IgA nephropathy
Disease control
Ongoing
This study tests a new drug called sparsentan against a standard blood pressure medication in 406 adults with IgA nephropathy, a kidney disease. The goal is to see if sparsentan can better protect the kidneys over about 2 years by reducing protein in the urine and slowing kidney …
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC